FGF9 and diabetic kidney disease: Our network pharmacology analysis showed that estradiol can improve the expression of abnormally down-regulated DEIRGs such as GHR, TGFBR3, FYN, and FGF9. Thus, estradiol can inhibit the occurrence or development of DKD by acting on at least 4 gene targets.